Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where P. Young is active.

Publication


Featured researches published by P. Young.


Journal of The American Academy of Dermatology | 1997

Indomethacin treatment of eighteen patients with Sweet's syndrome

Sylvie Jeanfils; Pascal Joly; P. Young; Christine Le Corvaisier-Pieto; Elisabeth Thomine; Phillippe Lauret

BACKGROUND The standard treatment for Sweets syndrome (acute febrile neutrophilic dermatosis) is oral corticosteroids. Despite a good initial response, the disease is characterized by frequent relapses. OBJECTIVE Our purpose was to test the therapeutic effect of the nonsteroidal antiinflammatory drug indomethacin on Sweets syndrome. METHODS All patients with Sweets syndrome observed during a 4-year period were given indomethacin, 150 mg/day for the first week and 100 mg/day for two additional weeks. The therapeutic response was assessed on days 4, 7, 14, 30, and 180. RESULTS Seventeen of 18 patients had a good initial response; fever and arthralgias were markedly attenuated within 48 hours and eruptions cleared between 7 and 14 days. The remaining patients cutaneous lesions continued to develop and were successfully treated with prednisone (1 mg/kg/day). The only side effect of indomethacin treatment was epigastric pain in two patients. No patient had a relapse after discontinuation of indomethacin (mean followup, 20.1 months). CONCLUSION Indomethacin is a safe and effective treatment for Sweets syndrome.


American Journal of Clinical Pathology | 2002

Value of Interphase FISH for the Diagnosis of t(11;14)(q13;q32) on Skin Lesions of Mantle Cell Lymphoma

Pierre Dubus; P. Young; M. Beylot-Barry; Marc A. Belaud-Rotureau; Philippe Courville; Béatrice Vergier; Marie Parrens; Bernard Lenormand; Pascal Joly; Jean Philippe Merlio

The diagnosis of skin lesions of mantle cell lymphoma (MCL) may be difficult at the onset of the disease. We observed 2 patients with papules of the trunk and 1 with diffuse infiltration of the trunk and the face and 2 subcutaneous nodules. Skin samples showed diffuse infiltration of the dermis (n = 1) or perivascular infiltration (n = 2). The infiltrate corresponded to centrocytic cells (n = 2) or pleomorphic blastoid cells (n = 1) with a B-cell phenotype: CD3-, CD5+ (2/3), CD20+, CD23-, and CD43+. In only 1 case was cyclin D1 immunoreactivity detected, and the t(11;l4)(q13;q32) breakpoint was amplified from both lymph node and skin DNA. Competitive reverse transcriptase-polymerase chain reaction was not contributive for skin specimens. In all 3 cases, interphase fluorescence in situ hybridization (FISH) demonstrated t(11;14) fusion signals either on paraffin sections or on fresh frozen touch preparations of skin biopsies. The recognition of skin lesions of MCL from other B-cell infiltrates can be established by interphase FISH.


Annales De Dermatologie Et De Venereologie | 2007

Lymphangiosarcome traité par doxorubicine liposomale (Caelyx

E. Verdier; P. Carvalho; P. Young; Philippe Musette; P. Courville; P. Joly

Resume Introduction Le lymphangiosarcome est une tumeur de mauvais pronostic. Son traitement chimiotherapique repose principalement sur les anthracyclines, dont l’utilisation est difficile chez les malades âges du fait de leur toxicite. Nous rapportons l’observation d’une femme âgee dont le lymphangiosarcome a, dans un premier temps, repondu a la doxorubicine (Caelyx ® ), anthracycline de moindre toxicite. Observation Une femme de 70 ans ayant un lymphœdeme sequellaire d’une neoplasie mammaire a developpe un lymphangiosarcome du bras et de la region pectorale realisant une enorme tumeur saignotante. Un traitement par doxorubicine (50 mg/m 2 ) etait instaure. Des la premiere cure, on notait une diminution de la masse tumorale et des saignements. Une regression de 90 p. 100 de la tumeur et une recuperation partielle de la fonction du membre superieur gauche etaient obtenues apres cinq cures. Deux mois apres l’arret du traitement, le lymphangiosarcome recidivait et la malade decedait. Discussion Le Caelyx ® a entraine une regression tumorale importante ainsi qu’un excellent effet antalgique et hemostatique avec une bonne tolerance. Une remission complete par le Caelyx ® d’un angiosarcome du cuir chevelu a ete recemment rapportee. Ce traitement pourrait etre une alternative therapeutique dans les lymphangiosarcomes inoperables notamment chez les malades âges.


Journal of The American Academy of Dermatology | 2004

Osteoarticular complications of erysipelas

Nadia Coste; G. Perceau; J. Leone; P. Young; Francis Carsuzaa; Karine Bernardeau; Philippe Bernard

BACKGROUND Rare osteoarticular complications occurring after erysipelas have been reported. We describe 9 patients in whom various osteoarticular complications developed during erysipelas. OBJECTIVE We sought to analyze osteoarticular complications during erysipelas, paying special attention to clinical, bacteriologic, and radiologic data. METHODS Data were retrospectively recorded from the files of patients seen in 3 dermatologic centers between 1998 and 2000. They included laboratory tests, bacteriologic cultures, radiologic investigations, and treatment modalities and outcome of both erysipelas and osteoarticular complications. RESULTS We observed 9 patients (7 men and 2 women; mean age 49.6 years) who first presented with typical erysipelas of the lower limb and then osteoarticular complications developed during the course of their disease, always localized to a joint contiguous to the erysipelas plaque. These complications included: relatively benign complications, ie, bursitis (n = 5) or algodystrophy (n = 1), occurring after erysipelas with favorable course; and more severe complications, ie, osteitis (n = 1), arthritis (n = 1), and septic tendinitis (n = 1), occurring after erysipelas characterized by local cutaneous complications (abscess, necrosis). CONCLUSIONS Osteoarticular complications of erysipelas can be divided into the 2 groups of nonseptic complications (mainly bursitis), which are characterized by a favorable outcome, and septic complications (osteitis, arthritis, tendinitis), which require specific, often prolonged treatment and, sometimes, operation. Their diagnosis is on the basis of clinical and radiologic findings rather than joint aspirations, which are usually not possible through infected skin tissue.


Annales De Dermatologie Et De Venereologie | 2007

Complications liées à l’exérèse du ganglion sentinelle dans le mélanome

E. Verdier; I. Auquit-Auckbur; P. Young; C. Corven; J. Chomant; P. Courville; P. Vera; P.-Y. Milliez; P. Joly

Resume Introduction Peu d’etudes ont evalue les complications survenues apres exerese du ganglion sentinelle chez les malades atteints de melanome. Le but de ce travail etait d’etudier les complications liees a la technique d’exerese du ganglion sentinelle chez les malades atteints de melanome. Malades et methodes Tous les malades ayant eu une exerese du ganglion sentinelle, entre mars 2000 et decembre 2002, ont ete inclus dans cette etude retrospective. Les malades ayant un ganglion envahi histologiquement et ayant eu secondairement un curage ganglionnaire ont ete exclus. La duree moyenne de suivi des malades etait de 12,6 ± 8,8 mois apres l’exerese. Les complications observees ont ete classees en complications precoces (survenant moins d’un mois apres l’intervention), ou tardives, passe ce delai. Resultats Quarante malades (17 hommes, et 23 femmes), issus d’une serie de 61 malades atteints de melanome ayant eu l’exerese de leur ganglion sentinelle, ont ete inclus. Quatorze complications ont ete observees chez dix malades (25 p. 100). Les deux complications precoces ont ete un hematome sur cicatrice et une thrombose veineuse compliquee d’embolie pulmonaire. Douze complications tardives ont ete observees : cinq lymphœdemes moderes, deux cicatrices hypertrophiques, quatre cicatrices douloureuses et une lymphorrhee. Trente-trois pour cent des complications observees interessaient le site inguinal. Discussion La morbidite de la technique d’exerese du ganglion sentinelle doit etre prise en compte dans l’evaluation de cette technique, surtout si son interet therapeutique n’etait pas montre par les etudes en cours.


Annales De Dermatologie Et De Venereologie | 2006

Érythème nécrolytique migrateur au cours d’une maladie de Waldmann

Sophie Baricault; J.C. Soubrane; P. Courville; P. Young; P. Joly

Resume Introduction Nous rapportons un cas d’erytheme necrolytique migrateur associe a une maladie de Waldmann. Observation Un homme de 55 ans,ayant une maladie de Waldmann depuis 20 ans, a ete hospitalise pour une eruption du tronc et des membres, faite de lesions annulaires a contours polycycliques avec collerette de desquamation peripherique, evocatrice d’un erytheme necrolytique migrateur. Une alimentation enterale hyperprotidique et enrichie en acides gras a entraine une amelioration rapide de son etat cutane. Discussion La maladie de Waldmann est caracterisee par des lymphangiectasies intestinales responsables d’une enteropathie exsudative a l’origine de pertes protidiques et d’un defaut d’absorption des acides gras.La physiopathologie de l’erytheme necrolytique migrateur est imparfaitement comprise. L’hyperglucagonemie ne semble pas etre le seul mecanisme en cause. La survenue d’un erytheme necrolytique migrateur au cours d’une maladie de Waldmann renforce les hypotheses physiopathologiques actuelles suggerant le role de l’hypoprotidemie et du deficit plasmatique en acides amines dans l’erytheme necrolytique migrateur.


Annales De Dermatologie Et De Venereologie | 2002

Chronic eczematiform eruption in the elderly

Morin C; P. Joly; Ph. Courville; P. Young; Richard C; X. Balguerie; Lauret P


Annales De Dermatologie Et De Venereologie | 1995

Association of lichen sclerosus and monomelic scleroderma

Lampert A; Fortier-Beaulieu M; Thomine E; P. Young; Lauret P


Annales De Dermatologie Et De Venereologie | 2000

Syndrome d'activation macrophagique et mélanome métastatique : 3 cas

N. Cordel; C. Le Corvaisier-Pieto; P. Young; B. Lenormand; Ph. Courville; J.C. Soubrane; P. Joly; Lauret P


Journal of The American Academy of Dermatology | 2004

Erizipelin Osteoartiküler Komplikasyonları

Nadia Coste; G. Perceau; J. Leone; P. Young; Francis Carsuzaa; Karine Bernardeau; vePhilippe Bernard Reims; Rouen ve Toulon; Fransa

Collaboration


Dive into the P. Young's collaboration.

Top Co-Authors

Avatar

P. Joly

French Institute of Health and Medical Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bernard Guillot

University of Montpellier

View shared research outputs
Top Co-Authors

Avatar

E. Puzenat

University of Franche-Comté

View shared research outputs
Researchain Logo
Decentralizing Knowledge